Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    RAPTOR novartis
Previous Study | Return to List | Next Study

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03802630
Recruitment Status : Not yet recruiting
First Posted : January 14, 2019
Last Update Posted : January 14, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

Condition or disease Intervention/treatment Phase
Branch Retinal Vein Occlusion Drug: Brolucizumab 6 mg Drug: Aflibercept 2 mg Other: Sham injection Phase 3

Detailed Description:
Following a 4-week maximum screening period, patients will be randomized and treated for approximately 76 weeks. Treatment visits will be scheduled in 4-week intervals. After 6 initial monthly injections of brolucizumab or aflibercept (loading phase), subjects will enter a one-year individualized flexible treatment (IFT) phase. During the IFT phase, an assessment of disease stability will be performed at each monthly visit and subjects will receive either an active or a sham injection. Treatment with active will be interrupted when disease stability is reached. Maximum study duration per patient is 80 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: A masked evaluating investigator will be responsible for all aspects of the study except the injections and the safety assessment following the injections. An unmasked treating investigator will perform the injections and assess patient safety following the injections.
Primary Purpose: Treatment
Official Title: An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
Estimated Study Start Date : July 23, 2019
Estimated Primary Completion Date : September 17, 2021
Estimated Study Completion Date : August 2, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema

Arm Intervention/treatment
Experimental: Brolucizumab 6 mg
1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
Drug: Brolucizumab 6 mg
Solution for injection (intravitreal use)
Other Names:
  • RTH258
  • ESBA1008

Other: Sham injection
Empty sterile syringe without a needle administered as a sham injection for masking purposes

Active Comparator: Aflibercept 2 mg
1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
Drug: Aflibercept 2 mg
Solution for injection (Intravitreal use)
Other Name: EYLEA®

Other: Sham injection
Empty sterile syringe without a needle administered as a sham injection for masking purposes




Primary Outcome Measures :
  1. Change from baseline in best-corrected visual acuity (BCVA) at Week 24 [ Time Frame: Baseline, Week 24 ]
    Assessed with ETDRS visual acuity testing charts


Secondary Outcome Measures :
  1. Change from baseline in BCVA averaged over Week 40 to Week 52 and Week 64 to Week 76 [ Time Frame: Week 40 to Week 52, Week 64 to Week 76 ]
    Assessed with ETDRS visual acuity testing charts

  2. Change from baseline in BCVA by visit up to Week 76 [ Time Frame: Baseline to Week 76 ]
    Assessed with ETDRS visual acuity testing charts

  3. Proportion of study eyes with a gain ≥ 5, 10 and 15 letters in BCVA by visit compared to baseline [ Time Frame: Baseline to Week 76 ]
    Assessed with ETDRS visual acuity testing charts

  4. Proportion of study eyes with a loss ≥ 5, 10 and 15 letters in BCVA by visit compared to baseline [ Time Frame: Baseline to Week 76 ]
    Assessed with ETDRS visual acuity testing charts

  5. Change from baseline in central subfield thickness (CSFT) averaged over Week 40 to Week 52 and Week 64 to Week 76 [ Time Frame: Week 40 to Week 52 and Week 64 to Week 76 ]
    CSFT measured in µm by Spectral Domain Optical Coherence Tomography (SD-OCT)

  6. Change from baseline in CSFT by visit up to Week 76 [ Time Frame: Baseline to Week 76 ]
    CSFT measured in µm by SD-OCT

  7. Proportion of study eyes with presence of retinal fluid (intra- and/or subretinal fluid) by visit up to Week 76 [ Time Frame: Baseline to Week 76 ]
    Presence of retinal fluid (intra- and/or subretinal fluid) assessed by SD-OCT

  8. Proportion of study eyes with a CSFT < 300 µm by visit up to Week 76 [ Time Frame: Baseline to Week 76 ]
    CSFT measured in µm

  9. Number of injections between Week 24 and Week 52 and between Week 24 and Week 76 [ Time Frame: Week 24 to Week 52 and Week 24 to Week 76 ]
    Number of administered injections

  10. Time to first re-treatment between Week 24 and Week 76 [ Time Frame: Week 24 to Week 76 ]
    Time to first injection after Week 24

  11. Incidence of ocular and non-ocular AEs up to Week 52 and Week 76 [ Time Frame: Baseline to Week 76 ]
    Incidence of ocular and non-ocular AEs

  12. Change from baseline in patient reported outcomes (NEI VFQ-25) at Week 24, Week 52 and Week 76 [ Time Frame: Baseline, Week 24, Week 52 and Week 76 ]
    The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) measures the influence of visual disability and visual symptoms on general health domains

  13. Anti-drug antibody (ADA) status at screening and Week 4, Week 12, Week 24, Week 36, Week 52 and Week 76 [ Time Frame: Screening, Week 4, Week 12, Week 24, Week 36, Week 52 and Week 76 ]
    Titration of ADA



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent must be obtained prior to participation in the study.
  • Patients with visual impairment due to ME secondary to BRVO diagnosed < 6 months prior to screening.
  • BCVA score between 78 and 23 letters, inclusive, using ETDRS visual acuity testing charts (approximate Snellen equivalent of 20/32 to 20/320) at both screening and baseline visits.

Exclusion criteria

  • Concomitant conditions or ocular disorders in the study eye at screening or baseline which could, in the opinion of the investigator, prevent response to study treatment or may confound interpretation of study results, compromise visual acuity or require medical or surgical intervention during the first 12-month study period (e.g. structural damage of the fovea, vitreous hemorrhage, retinal vascular occlusion other than BRVO, retinal detachment, macular hole, or choroidal neovascularization of any cause, diabetic retinopathy (except mild non-proliferative) and diabetic macular edema). Hemiretinal vein occlusion should be excluded.
  • Any active intraocular or periocular infection or active intraocular inflammation (e.g. infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in study eye at screening or baseline
  • Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) > 25 mmHg on medication, or according to investigator's judgment, at screening or baseline
  • Presence of amblyopia, amaurosis or ocular disorders in the fellow eye with BCVA < 20/200 at screening (except when due to conditions whose surgery may improve VA, e.g. cataract)
  • Previous treatment with any anti-VEGF therapy or investigational drugs in the study eye at any time prior to baseline
  • Previous use of intraocular or periocular steroids in study eye at any time prior to baseline
  • Macular laser photocoagulation (focal/grid) in the study eye at any time prior to baseline and peripheral laser photocoagulation in the study eye within 3 months prior to the baseline
  • Intraocular surgery in the study eye during the 3‑month period prior to baseline
  • Vitreoretinal surgery in the study eye at any time prior to baseline
  • Aphakia with the absence of posterior capsule in the study eye

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03802630


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals +41613241111

Sponsors and Collaborators
Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03802630     History of Changes
Other Study ID Numbers: CRTH258C2301
First Posted: January 14, 2019    Key Record Dates
Last Update Posted: January 14, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Visual impairment
Macular edema
Branch retinal vein occlusion
BRVO
Brolucizumab
Aflibercept
Vascular endothelial growth factor
VEGF
anti-VEGF
Additional relevant MeSH terms:
Layout table for MeSH terms
Vision Disorders
Vision, Low
Macular Edema
Retinal Vein Occlusion
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Venous Thrombosis
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases